Finanzen von CalciMedica Inc (CALC)CALCCalciMedica Inc

Evaluating the bottom line, CalciMedica Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -365.70%, provide a clear picture of how effectively CALC converts its operational activities into shareholder value.

In the context of the broader market, CALC competes directly with industry leaders such as ADVB and MDCX. With a market capitalization of $16.05M, it holds a significant position in the sector. When comparing efficiency, CALC's gross margin of N/A stands against ADVB's N/A and MDCX's N/A. Such benchmarking helps identify whether CalciMedica Inc is trading at a premium or discount relative to its financial performance.

CalciMedica has reported significant losses, including a net income loss of $7.65 million in Q2 2026 and a negative EPS of -0.45. The company's financial health is concerning, with a debt to equity ratio of 166.88% and a current ratio of 5.58, indicating potential liquidity issues.